Global Balantidiasis Market
Global Balantidiasis Market

Balantidiasis Comprehensive Study by Treatment (Antibiotics, Appendectomy), Diagnosis (Physical Examination, Stool Examination, Sigmoidoscopy, Biopsy), End User (Hospitals, Clinics, Diagnostic Centers) Players and Region - Global Market Outlook to 2025

Balantidiasis Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 217 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Balantidiasis Market Scope
Balantidiasis is the infection caused by the Balantidium coli, which is the intestinal protozoan parasite. Humans and other mammals can become infected with Balantidium coli by ingesting infective cysts from water and food that is contaminated by feces. Mostly asymptomatic, Balantidium infection can cause such symptoms as abdominal pain and diarrhea. Balantidium coli is found throughout the world, but it is most prevalent in tropical and subtropical regions and developing nations. Because pigs are an animal reservoir, human infections occur more commonly in areas where pigs are raised, especially if good hygiene is not practiced.

The Balantidiasis market study is segmented and major geographies with country level break-up.

In this market, companies are completely focused on research and development to develop drugs or devices. The companies are exploring the market in new regions by expansions, investments, collaboration, and partnership as their preferred strategies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Balantidiasis market throughout the predicted period.

Fougera Pharmaceuticals Inc. (United States), Koninklijke Philips N.V. (Netherlands), Johnson & Johnson Services Inc. (United States), Abbott (United States), Medtronic (Ireland), Pfizer Inc. (United States), Nurotron Biotechnology Co. Ltd. (United States), Sonova Holding AG (Switzerland), C.R. Bard Inc. (United States), 3M (United States) and NuVasive, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Microport Scientific Corporation (China), Akorn, Inc. (United States), Globus Medical, Inc. (United States), Sandoz International GmbH (Germany) and MED-EL (Austria).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Balantidiasis market by Type, Application and Region.

On the basis of geography, the market of Balantidiasis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Upsurging Demand for Antibiotics for the Balantidiasis Treatment

Market Drivers
  • Increasing Prevalence of Gastrointestinal Disorders
  • Availability of Treatment of Balantidiasis

Opportunities
  • Rising Awareness about the Diseases Transmitted Through Fecal-Oral Route
  • Growing Demand for Balantidiasis Prevalence’s across the Developing Nations

Restraints
  • Competition among Existing Market Players

Challenges
  • The Dearth of Skilled Healthcare Providers
  • Adverse Effects Associated with Drugs


Key Target Audience
Drug Manufacturers, Drug Suppliers, Medical Research Laboratories, Research and Development (R&D) Companies, Market Research and Consulting Service Providers, Potential Investors and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Treatment
  • Antibiotics
  • Appendectomy

By Diagnosis
  • Physical Examination
  • Stool Examination
  • Sigmoidoscopy
  • Biopsy

By End User
  • Hospitals
  • Clinics
  • Diagnostic Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Gastrointestinal Disorders
      • 3.2.2. Availability of Treatment of Balantidiasis
    • 3.3. Market Challenges
      • 3.3.1. The Dearth of Skilled Healthcare Providers
      • 3.3.2. Adverse Effects Associated with Drugs
    • 3.4. Market Trends
      • 3.4.1. Upsurging Demand for Antibiotics for the Balantidiasis Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Balantidiasis, by Treatment, Diagnosis, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Balantidiasis (Value)
      • 5.2.1. Global Balantidiasis by: Treatment (Value)
        • 5.2.1.1. Antibiotics
        • 5.2.1.2. Appendectomy
      • 5.2.2. Global Balantidiasis by: Diagnosis (Value)
        • 5.2.2.1. Physical Examination
        • 5.2.2.2. Stool Examination
        • 5.2.2.3. Sigmoidoscopy
        • 5.2.2.4. Biopsy
      • 5.2.3. Global Balantidiasis by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Diagnostic Centers
      • 5.2.4. Global Balantidiasis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Balantidiasis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Fougera Pharmaceuticals Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Koninklijke Philips N.V. (Netherlands)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson Services Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Medtronic (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Nurotron Biotechnology Co. Ltd. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sonova Holding AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. C.R. Bard Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. 3M (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. NuVasive, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Balantidiasis Sale, by Treatment, Diagnosis, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Balantidiasis (Value)
      • 7.2.1. Global Balantidiasis by: Treatment (Value)
        • 7.2.1.1. Antibiotics
        • 7.2.1.2. Appendectomy
      • 7.2.2. Global Balantidiasis by: Diagnosis (Value)
        • 7.2.2.1. Physical Examination
        • 7.2.2.2. Stool Examination
        • 7.2.2.3. Sigmoidoscopy
        • 7.2.2.4. Biopsy
      • 7.2.3. Global Balantidiasis by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Diagnostic Centers
      • 7.2.4. Global Balantidiasis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Balantidiasis: by Treatment(USD Million)
  • Table 2. Balantidiasis Antibiotics , by Region USD Million (2014-2019)
  • Table 3. Balantidiasis Appendectomy , by Region USD Million (2014-2019)
  • Table 4. Balantidiasis: by Diagnosis(USD Million)
  • Table 5. Balantidiasis Physical Examination , by Region USD Million (2014-2019)
  • Table 6. Balantidiasis Stool Examination , by Region USD Million (2014-2019)
  • Table 7. Balantidiasis Sigmoidoscopy , by Region USD Million (2014-2019)
  • Table 8. Balantidiasis Biopsy , by Region USD Million (2014-2019)
  • Table 9. Balantidiasis: by End User(USD Million)
  • Table 10. Balantidiasis Hospitals , by Region USD Million (2014-2019)
  • Table 11. Balantidiasis Clinics , by Region USD Million (2014-2019)
  • Table 12. Balantidiasis Diagnostic Centers , by Region USD Million (2014-2019)
  • Table 13. South America Balantidiasis, by Country USD Million (2014-2019)
  • Table 14. South America Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 15. South America Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 16. South America Balantidiasis, by End User USD Million (2014-2019)
  • Table 17. Brazil Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 18. Brazil Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 19. Brazil Balantidiasis, by End User USD Million (2014-2019)
  • Table 20. Argentina Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 21. Argentina Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 22. Argentina Balantidiasis, by End User USD Million (2014-2019)
  • Table 23. Rest of South America Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 24. Rest of South America Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 25. Rest of South America Balantidiasis, by End User USD Million (2014-2019)
  • Table 26. Asia Pacific Balantidiasis, by Country USD Million (2014-2019)
  • Table 27. Asia Pacific Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 28. Asia Pacific Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 29. Asia Pacific Balantidiasis, by End User USD Million (2014-2019)
  • Table 30. China Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 31. China Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 32. China Balantidiasis, by End User USD Million (2014-2019)
  • Table 33. Japan Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 34. Japan Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 35. Japan Balantidiasis, by End User USD Million (2014-2019)
  • Table 36. India Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 37. India Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 38. India Balantidiasis, by End User USD Million (2014-2019)
  • Table 39. South Korea Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 40. South Korea Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 41. South Korea Balantidiasis, by End User USD Million (2014-2019)
  • Table 42. Taiwan Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 43. Taiwan Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 44. Taiwan Balantidiasis, by End User USD Million (2014-2019)
  • Table 45. Australia Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 46. Australia Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 47. Australia Balantidiasis, by End User USD Million (2014-2019)
  • Table 48. Rest of Asia-Pacific Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 49. Rest of Asia-Pacific Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 50. Rest of Asia-Pacific Balantidiasis, by End User USD Million (2014-2019)
  • Table 51. Europe Balantidiasis, by Country USD Million (2014-2019)
  • Table 52. Europe Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 53. Europe Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 54. Europe Balantidiasis, by End User USD Million (2014-2019)
  • Table 55. Germany Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 56. Germany Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 57. Germany Balantidiasis, by End User USD Million (2014-2019)
  • Table 58. France Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 59. France Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 60. France Balantidiasis, by End User USD Million (2014-2019)
  • Table 61. Italy Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 62. Italy Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 63. Italy Balantidiasis, by End User USD Million (2014-2019)
  • Table 64. United Kingdom Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 65. United Kingdom Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 66. United Kingdom Balantidiasis, by End User USD Million (2014-2019)
  • Table 67. Netherlands Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 68. Netherlands Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 69. Netherlands Balantidiasis, by End User USD Million (2014-2019)
  • Table 70. Rest of Europe Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 71. Rest of Europe Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 72. Rest of Europe Balantidiasis, by End User USD Million (2014-2019)
  • Table 73. MEA Balantidiasis, by Country USD Million (2014-2019)
  • Table 74. MEA Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 75. MEA Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 76. MEA Balantidiasis, by End User USD Million (2014-2019)
  • Table 77. Middle East Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 78. Middle East Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 79. Middle East Balantidiasis, by End User USD Million (2014-2019)
  • Table 80. Africa Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 81. Africa Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 82. Africa Balantidiasis, by End User USD Million (2014-2019)
  • Table 83. North America Balantidiasis, by Country USD Million (2014-2019)
  • Table 84. North America Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 85. North America Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 86. North America Balantidiasis, by End User USD Million (2014-2019)
  • Table 87. United States Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 88. United States Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 89. United States Balantidiasis, by End User USD Million (2014-2019)
  • Table 90. Canada Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 91. Canada Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 92. Canada Balantidiasis, by End User USD Million (2014-2019)
  • Table 93. Mexico Balantidiasis, by Treatment USD Million (2014-2019)
  • Table 94. Mexico Balantidiasis, by Diagnosis USD Million (2014-2019)
  • Table 95. Mexico Balantidiasis, by End User USD Million (2014-2019)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Balantidiasis: by Treatment(USD Million)
  • Table 108. Balantidiasis Antibiotics , by Region USD Million (2020-2025)
  • Table 109. Balantidiasis Appendectomy , by Region USD Million (2020-2025)
  • Table 110. Balantidiasis: by Diagnosis(USD Million)
  • Table 111. Balantidiasis Physical Examination , by Region USD Million (2020-2025)
  • Table 112. Balantidiasis Stool Examination , by Region USD Million (2020-2025)
  • Table 113. Balantidiasis Sigmoidoscopy , by Region USD Million (2020-2025)
  • Table 114. Balantidiasis Biopsy , by Region USD Million (2020-2025)
  • Table 115. Balantidiasis: by End User(USD Million)
  • Table 116. Balantidiasis Hospitals , by Region USD Million (2020-2025)
  • Table 117. Balantidiasis Clinics , by Region USD Million (2020-2025)
  • Table 118. Balantidiasis Diagnostic Centers , by Region USD Million (2020-2025)
  • Table 119. South America Balantidiasis, by Country USD Million (2020-2025)
  • Table 120. South America Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 121. South America Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 122. South America Balantidiasis, by End User USD Million (2020-2025)
  • Table 123. Brazil Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 124. Brazil Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 125. Brazil Balantidiasis, by End User USD Million (2020-2025)
  • Table 126. Argentina Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 127. Argentina Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 128. Argentina Balantidiasis, by End User USD Million (2020-2025)
  • Table 129. Rest of South America Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 130. Rest of South America Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 131. Rest of South America Balantidiasis, by End User USD Million (2020-2025)
  • Table 132. Asia Pacific Balantidiasis, by Country USD Million (2020-2025)
  • Table 133. Asia Pacific Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 134. Asia Pacific Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 135. Asia Pacific Balantidiasis, by End User USD Million (2020-2025)
  • Table 136. China Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 137. China Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 138. China Balantidiasis, by End User USD Million (2020-2025)
  • Table 139. Japan Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 140. Japan Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 141. Japan Balantidiasis, by End User USD Million (2020-2025)
  • Table 142. India Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 143. India Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 144. India Balantidiasis, by End User USD Million (2020-2025)
  • Table 145. South Korea Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 146. South Korea Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 147. South Korea Balantidiasis, by End User USD Million (2020-2025)
  • Table 148. Taiwan Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 149. Taiwan Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 150. Taiwan Balantidiasis, by End User USD Million (2020-2025)
  • Table 151. Australia Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 152. Australia Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 153. Australia Balantidiasis, by End User USD Million (2020-2025)
  • Table 154. Rest of Asia-Pacific Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 155. Rest of Asia-Pacific Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 156. Rest of Asia-Pacific Balantidiasis, by End User USD Million (2020-2025)
  • Table 157. Europe Balantidiasis, by Country USD Million (2020-2025)
  • Table 158. Europe Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 159. Europe Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 160. Europe Balantidiasis, by End User USD Million (2020-2025)
  • Table 161. Germany Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 162. Germany Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 163. Germany Balantidiasis, by End User USD Million (2020-2025)
  • Table 164. France Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 165. France Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 166. France Balantidiasis, by End User USD Million (2020-2025)
  • Table 167. Italy Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 168. Italy Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 169. Italy Balantidiasis, by End User USD Million (2020-2025)
  • Table 170. United Kingdom Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 171. United Kingdom Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 172. United Kingdom Balantidiasis, by End User USD Million (2020-2025)
  • Table 173. Netherlands Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 174. Netherlands Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 175. Netherlands Balantidiasis, by End User USD Million (2020-2025)
  • Table 176. Rest of Europe Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 177. Rest of Europe Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 178. Rest of Europe Balantidiasis, by End User USD Million (2020-2025)
  • Table 179. MEA Balantidiasis, by Country USD Million (2020-2025)
  • Table 180. MEA Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 181. MEA Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 182. MEA Balantidiasis, by End User USD Million (2020-2025)
  • Table 183. Middle East Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 184. Middle East Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 185. Middle East Balantidiasis, by End User USD Million (2020-2025)
  • Table 186. Africa Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 187. Africa Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 188. Africa Balantidiasis, by End User USD Million (2020-2025)
  • Table 189. North America Balantidiasis, by Country USD Million (2020-2025)
  • Table 190. North America Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 191. North America Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 192. North America Balantidiasis, by End User USD Million (2020-2025)
  • Table 193. United States Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 194. United States Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 195. United States Balantidiasis, by End User USD Million (2020-2025)
  • Table 196. Canada Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 197. Canada Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 198. Canada Balantidiasis, by End User USD Million (2020-2025)
  • Table 199. Mexico Balantidiasis, by Treatment USD Million (2020-2025)
  • Table 200. Mexico Balantidiasis, by Diagnosis USD Million (2020-2025)
  • Table 201. Mexico Balantidiasis, by End User USD Million (2020-2025)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Balantidiasis: by Treatment USD Million (2014-2019)
  • Figure 5. Global Balantidiasis: by Diagnosis USD Million (2014-2019)
  • Figure 6. Global Balantidiasis: by End User USD Million (2014-2019)
  • Figure 7. South America Balantidiasis Share (%), by Country
  • Figure 8. Asia Pacific Balantidiasis Share (%), by Country
  • Figure 9. Europe Balantidiasis Share (%), by Country
  • Figure 10. MEA Balantidiasis Share (%), by Country
  • Figure 11. North America Balantidiasis Share (%), by Country
  • Figure 12. Global Balantidiasis share by Players 2019 (%)
  • Figure 13. Global Balantidiasis share by Players (Top 3) 2019(%)
  • Figure 14. Global Balantidiasis share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Fougera Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Fougera Pharmaceuticals Inc. (United States) Revenue: by Geography 2019
  • Figure 18. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 19. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2019
  • Figure 20. Johnson & Johnson Services Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Johnson & Johnson Services Inc. (United States) Revenue: by Geography 2019
  • Figure 22. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 23. Abbott (United States) Revenue: by Geography 2019
  • Figure 24. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 25. Medtronic (Ireland) Revenue: by Geography 2019
  • Figure 26. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 28. Nurotron Biotechnology Co. Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Nurotron Biotechnology Co. Ltd. (United States) Revenue: by Geography 2019
  • Figure 30. Sonova Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Sonova Holding AG (Switzerland) Revenue: by Geography 2019
  • Figure 32. C.R. Bard Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. C.R. Bard Inc. (United States) Revenue: by Geography 2019
  • Figure 34. 3M (United States) Revenue, Net Income and Gross profit
  • Figure 35. 3M (United States) Revenue: by Geography 2019
  • Figure 36. NuVasive, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. NuVasive, Inc. (United States) Revenue: by Geography 2019
  • Figure 38. Global Balantidiasis: by Treatment USD Million (2020-2025)
  • Figure 39. Global Balantidiasis: by Diagnosis USD Million (2020-2025)
  • Figure 40. Global Balantidiasis: by End User USD Million (2020-2025)
  • Figure 41. South America Balantidiasis Share (%), by Country
  • Figure 42. Asia Pacific Balantidiasis Share (%), by Country
  • Figure 43. Europe Balantidiasis Share (%), by Country
  • Figure 44. MEA Balantidiasis Share (%), by Country
  • Figure 45. North America Balantidiasis Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Fougera Pharmaceuticals Inc. (United States)
  • Koninklijke Philips N.V. (Netherlands)
  • Johnson & Johnson Services Inc. (United States)
  • Abbott (United States)
  • Medtronic (Ireland)
  • Pfizer Inc. (United States)
  • Nurotron Biotechnology Co. Ltd. (United States)
  • Sonova Holding AG (Switzerland)
  • C.R. Bard Inc. (United States)
  • 3M (United States)
  • NuVasive, Inc. (United States)
Additional players considered in the study are as follows:
Microport Scientific Corporation (China) , Akorn, Inc. (United States) , Globus Medical, Inc. (United States) , Sandoz International GmbH (Germany) , MED-EL (Austria)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation